开云app官网登录入口网页版-官方正版

#申请上市#

11篇内容 | 908人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1752882, encodeId=3c641e52882ee, content=<a href='/topic/show?id=342d699e211' target=_blank style='color:#2F92EE;'>#申请上市#</a>, objectTitle=驯鹿生物与信达生物共同开发的全人源BCMA CAR-T细胞伊基仑赛注射液新药申请上市, objectType=article, longId=728560, objectId=ec8be2856007, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec8be2856007, replyNumber=0, likeNumber=89, createdTime=2023-02-21, rootId=0, userName=photoman, userId=836636580373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec8be2856007, moduleTitle=驯鹿生物与信达生物共同开发的全人源BCMA CAR-T细胞伊基仑赛注射液新药申请上市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ec8be2856007)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752880, encodeId=54d81e52880c3, content=<a href='/topic/show?id=342d699e211' target=_blank style='color:#2F92EE;'>#申请上市#</a>, objectTitle=Bluebird突破性基因疗法Lenti-D申请上市！改善致死罕见病CALD患者长期生存结局, objectType=article, longId=201693, objectId=ec9320169308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec9320169308, replyNumber=0, likeNumber=58, createdTime=2021-01-19, rootId=0, userName=photoman, userId=836636580373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec9320169308, moduleTitle=Bluebird突破性基因疗法Lenti-D申请上市！改善致死罕见病CALD患者长期生存结局, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ec9320169308)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752881, encodeId=d5561e52881b4, content=<a href='/topic/show?id=342d699e211' target=_blank style='color:#2F92EE;'>#申请上市#</a>, objectTitle=默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市, objectType=article, longId=202883, objectId=f95120288352, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f95120288352, replyNumber=0, likeNumber=59, createdTime=2020-12-01, rootId=0, userName=photoman, userId=836636580373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f95120288352, moduleTitle=默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f95120288352)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752879, encodeId=ccda1e52879b3, content=<a href='/topic/show?id=342d699e211' target=_blank style='color:#2F92EE;'>#申请上市#</a>, objectTitle=背靠基因测序巨头，融资超20亿美元癌症诊断公司Grail申请上市, objectType=article, longId=200555, objectId=63162005553e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63162005553e, replyNumber=0, likeNumber=75, createdTime=2021-07-08, rootId=0, userName=photoman, userId=836636580373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63162005553e, moduleTitle=背靠基因测序巨头，融资超20亿美元癌症诊断公司Grail申请上市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=63162005553e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752876, encodeId=0a031e52876aa, content=<a href='/topic/show?id=342d699e211' target=_blank style='color:#2F92EE;'>#申请上市#</a>, objectTitle=中国丙肝市场再迎猛将 “吉四代”Vosevi申请上市！, objectType=article, longId=168374, objectId=a6371683e47d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6371683e47d, replyNumber=0, likeNumber=60, createdTime=2020-02-10, rootId=0, userName=photoman, userId=836636580373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6371683e47d, moduleTitle=中国丙肝市场再迎猛将 “吉四代”Vosevi申请上市！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a6371683e47d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752875, encodeId=99031e52875f2, content=<a href='/topic/show?id=342d699e211' target=_blank style='color:#2F92EE;'>#申请上市#</a>, objectTitle=国家药监局：这30个药，可直接申请上市, objectType=article, longId=163465, objectId=593716346542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=593716346542, replyNumber=0, likeNumber=66, createdTime=2019-10-20, rootId=0, userName=photoman, userId=836636580373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=593716346542, moduleTitle=国家药监局：这30个药，可直接申请上市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=593716346542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752878, encodeId=40021e528788d, content=<a href='/topic/show?id=342d699e211' target=_blank style='color:#2F92EE;'>#申请上市#</a>, objectTitle=大逆转，曾终止临床三期的AD药物aducanumab将申请上市昨日（10月22日），渤健（Biogen）和卫材（Eisai）联合宣布，在与美国FDA沟通后，渤健, objectType=article, longId=181821, objectId=ade018182134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ade018182134, replyNumber=0, likeNumber=79, createdTime=2019-11-30, rootId=0, userName=photoman, userId=836636580373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ade018182134, moduleTitle=大逆转，曾终止临床三期的AD药物aducanumab将申请上市昨日（10月22日），渤健（Biogen）和卫材（Eisai）联合宣布，在与美国FDA沟通后，渤健, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ade018182134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752877, encodeId=31081e5287779, content=<a href='/topic/show?id=342d699e211' target=_blank style='color:#2F92EE;'>#申请上市#</a>, objectTitle=又一个罕见病药物免临床申请上市, objectType=article, longId=176559, objectId=db8b1e65591a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db8b1e65591a, replyNumber=0, likeNumber=106, createdTime=2020-06-14, rootId=0, userName=photoman, userId=836636580373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db8b1e65591a, moduleTitle=又一个罕见病药物免临床申请上市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=db8b1e65591a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752874, encodeId=565f1e528744e, content=<a href='/topic/show?id=342d699e211' target=_blank style='color:#2F92EE;'>#申请上市#</a>, objectTitle=多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌, objectType=article, longId=162125, objectId=bf0c162125cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf0c162125cc, replyNumber=0, likeNumber=79, createdTime=2019-11-08, rootId=0, userName=photoman, userId=836636580373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf0c162125cc, moduleTitle=多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=bf0c162125cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752873, encodeId=9a3e1e5287392, content=<a href='/topic/show?id=342d699e211' target=_blank style='color:#2F92EE;'>#申请上市#</a>, objectTitle=重磅！国外上市急需药品可以直接在CDE申请上市，免做临床, objectType=article, longId=146231, objectId=0957146231f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0957146231f2, replyNumber=0, likeNumber=77, createdTime=2018-08-30, rootId=0, userName=photoman, userId=836636580373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0957146231f2, moduleTitle=重磅！国外上市急需药品可以直接在CDE申请上市，免做临床, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0957146231f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752872, encodeId=adc11e5287239, content=<a href='/topic/show?id=342d699e211' target=_blank style='color:#2F92EE;'>#申请上市#</a>, objectTitle=3期结果积极，肠易激综合征新药拟明年申请上市, objectType=article, longId=116079, objectId=6ec61160e991, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ec61160e991, replyNumber=0, likeNumber=86, createdTime=2017-10-30, rootId=0, userName=photoman, userId=836636580373, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ec61160e991, moduleTitle=3期结果积极，肠易激综合征新药拟明年申请上市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6ec61160e991)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

申请上市

2020-05-29

photoman (审核中...)

前往app查看评论内容

#申请上市#

驯鹿生物与信达生物共同开发的全人源BCMA CAR-T细胞伊基仑赛注射液新药申请上市

2023-02-21

photoman (审核中...)

前往app查看评论内容

#申请上市#

Bluebird突破性基因疗法Lenti-D申请上市！改善致死罕见病CALD患者长期生存结局

2021-01-19

photoman (审核中...)

前往app查看评论内容

#申请上市#

默沙东15价肺炎球菌结合疫苗2项III期研究成功，计划年底申请上市

2020-12-01

photoman (审核中...)

前往app查看评论内容

#申请上市#

背靠基因测序巨头，融资超20亿美元癌症诊断公司Grail申请上市

2021-07-08

photoman (审核中...)

前往app查看评论内容

#申请上市#

中国丙肝市场再迎猛将 “吉四代”Vosevi申请上市！

2020-02-10

photoman (审核中...)

前往app查看评论内容

#申请上市#

国家药监局：这30个药，可直接申请上市

2019-10-20

photoman (审核中...)

前往app查看评论内容

#申请上市#

大逆转，曾终止临床三期的AD药物aducanumab将申请上市昨日（10月22日），渤健（Biogen）和卫材（Eisai）联合宣布，在与美国FDA沟通后，渤健

2019-11-30

photoman (审核中...)

前往app查看评论内容

#申请上市#

又一个罕见病药物免临床申请上市

2020-06-14

photoman (审核中...)

前往app查看评论内容

#申请上市#

多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌

2019-11-08

photoman (审核中...)

前往app查看评论内容

#申请上市#

重磅！国外上市急需药品可以直接在CDE申请上市，免做临床

2018-08-30

photoman (审核中...)

前往app查看评论内容

#申请上市#

3期结果积极，肠易激综合征新药拟明年申请上市

2017-10-30

科室
- - 订阅+
  - 更多科室
工具
服务